PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-09-13
DOI
10.1038/srep32992
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer
- (2014) Rajani Kanteti et al. BMC CANCER
- HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
- (2014) Y J Liu et al. BRITISH JOURNAL OF CANCER
- Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer
- (2014) Cheng Ji et al. CANCER BIOLOGY & THERAPY
- Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer
- (2014) Jatin Roper et al. CANCER LETTERS
- Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
- (2014) Joseph D. Valentino et al. CLINICAL CANCER RESEARCH
- Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma
- (2014) Phyllis R. Wachsberger et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK+ anaplastic large cell lymphoma
- (2014) Farid Saei Hamedani et al. LEUKEMIA RESEARCH
- MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
- (2014) Rajani Kanteti et al. PLoS One
- Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
- (2013) Maria Serova et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis
- (2013) Hui Ren et al. CANCER LETTERS
- Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma
- (2013) Martha M. Kirstein et al. LIVER INTERNATIONAL
- Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
- (2013) O. Surriga et al. MOLECULAR CANCER THERAPEUTICS
- The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target
- (2013) Benjamin D. Ferguson et al. PLoS One
- Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
- (2012) W. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
- (2012) S. M. Brachmann et al. MOLECULAR CANCER THERAPEUTICS
- Unknown
- (2012) Rong Bu et al. MOLECULAR MEDICINE
- PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
- (2012) Lise Willems et al. Current Oncology Reports
- Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
- (2011) D. Koul et al. CLINICAL CANCER RESEARCH
- NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations
- (2011) EUNJU PARK et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone
- (2011) Yuhuan Zheng et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Update on Malignant Pleural Mesothelioma
- (2011) Nicholas Campbell et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells
- (2009) Yoshitaka Sekido CANCER SCIENCE
- Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells
- (2009) Koji Kawaguchi et al. CARCINOGENESIS
- Activation of native TRPC1/C5/C6 channels by endothelin-1 is mediated by both PIP3and PIP2in rabbit coronary artery myocytes
- (2009) Sohag N. Saleh et al. JOURNAL OF PHYSIOLOGY-LONDON
- PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription
- (2009) Rajani Kanteti et al. LABORATORY INVESTIGATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now